The Potential of Dendritic Cell Subsets in the Development of Personalized Immunotherapy for Cancer Treatment DOI Creative Commons
Anna V. Gorodilova, Kristina V. Kitaeva, Ivan Y. Filin

et al.

Current Issues in Molecular Biology, Journal Year: 2023, Volume and Issue: 45(10), P. 8053 - 8070

Published: Oct. 1, 2023

Since the discovery of dendritic cells (DCs) in 1973 by Ralph Steinman, a tremendous amount knowledge regarding these innate immunity has been accumulating. Their role regulating both and adaptive immune processes is gradually being uncovered. DCs are proficient antigen-presenting capable activating naive T-lymphocytes to initiate generate effective anti-tumor responses. Although DC-based immunotherapy not yielded significant results, substantial number ongoing clinical trials underscores relevance DC vaccines, particularly as adjunctive therapy or combination with other treatment options. This review presents an overview current human DCs, their classification, functions distinct populations. The stepwise process developing therapeutic vaccines treat oncological diseases discussed, along speculation on potential combined approaches modern immunotherapy.

Language: Английский

Reprogramming the Tumor Immune Microenvironment Through Activatable Photothermal Therapy and GSH depletion Using Liposomal Gold Nanocages to Potentiate Anti‐Metastatic Immunotherapy DOI
Jiayi Li,

Kaifan Zheng,

Luping Lin

et al.

Small, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 2, 2024

Abstract Cancer immunotherapy offers significant clinical benefits for patients with advanced or metastatic tumors. However, immunotherapeutic efficacy is often hindered by the tumor microenvironment's high redox levels, leading to variable patient outcomes. Herein, a therapeutic liposomal gold nanocage (MGL) innovatively developed based on photo‐triggered hyperthermia and releasable strategy combining glutathione (GSH) depletion remodel immune microenvironment, fostering more robust anti‐tumor response. MGL comprises thermosensitive liposome shell core loaded maleimide. The flexible promotes efficient uptake cancer cells, enabling targeted destruction through photothermal therapy while triggering immunogenic cell death maturation of antigen‐presenting cells. photoactivated release maleimide depletes intracellular GSH, increasing sensitivity oxidative stress thermal damage. Conversely, GSH reduction also diminishes immunosuppressive activity, enhances antigen presentation, activates T Moreover, decreases elevated levels heat shock proteins in further their hyperthermia. In summary, elicited systemic antitumor response depletion, facilitating an effective that reprograms microenvironment significantly inhibits primary This approach demonstrates considerable translational potential applicability.

Language: Английский

Citations

4
Personalized mRNA vaccines in glioblastoma therapy: from rational design to clinical trials DOI Creative Commons
Iman Karimi-Sani,

Zahra Molavi,

Samaneh Naderi

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Oct. 4, 2024

Abstract Glioblastomas (GBMs) are the most common and aggressive malignant brain tumors, presenting significant challenges for treatment due to their invasive nature localization in critical regions. Standard includes surgical resection followed by radiation adjuvant chemotherapy with temozolomide (TMZ). Recent advances immunotherapy, including use of mRNA vaccines, offer promising alternatives. This review focuses on emerging vaccines GBM treatment. We summarize recent advancements, evaluate current obstacles, discuss notable successes this field. Our analysis highlights that while have shown potential, is still experimental. Ongoing research clinical trials essential fully understand therapeutic potential. Future developments vaccine technology insights into GBM-specific immune responses may lead more targeted effective treatments. Despite promise, further crucial validate optimize effectiveness combating GBM. Graphical

Language: Английский

Citations

4
Advancing brain immunotherapy through functional nanomaterials DOI Creative Commons

Bhanu Nirosha Yalamandala,

Thi My Hue Huynh,

Hui-Wen Lien

et al.

Drug Delivery and Translational Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 9, 2025

Abstract Glioblastoma (GBM), a highly aggressive brain tumor, poses significant treatment challenges due to its immunosuppressive microenvironment and the immune privilege. Immunotherapy activating system T lymphocyte infiltration holds great promise against GBM. However, brain’s low immunogenicity difficulty of crossing blood-brain barrier (BBB) hinder therapeutic efficacy. Recent advancements in immune-actuated particles for targeted drug delivery have shown potential overcome these obstacles. These interact with BBB by rapidly reversibly disrupting structure, thereby significantly enhancing targeting penetrating delivery. The also minimizes long-term damage. At GBM, demonstrated effective chemotherapy, chemodynamic therapy, photothermal therapy (PTT), photodynamic (PDT), radiotherapy, or magnetotherapy, facilitating tumor disruption promoting antigen release. Additionally, components retained autologous tumor-associated antigens presented them dendritic cells (DCs), ensuring prolonged activation. This review explores mechanisms existing strategies, role nanomaterials immunotherapy. We discuss innovative particle-based approaches designed traverse mimicking innate functions improve outcomes tumors. Graphical

Language: Английский

Citations

0
Comprehensive review on glioblastoma: nanotechnology, immunotherapy and combined therapeutic approaches DOI Creative Commons

Ashish Dhiman,

ya N A Shah,

Dhwani Rana

et al.

RSC Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

The review highlights intersection of cutting-edge nanocarrier-based drug delivery, surface modification nanocarriers, immunotherapeutic interventions, and combined therapeutic approaches, which are critical for advancing glioblastoma treatment.

Language: Английский

Citations

0
Bioinspired Membrane‐Based Cancer Vaccines for Immunotherapy: Progress and Perspectives DOI
Ying Miao,

Jianlin Ge,

Longyi Zheng

et al.

Small, Journal Year: 2025, Volume and Issue: unknown

Published: April 21, 2025

Abstract Cancer vaccines hold promise for tumor immunotherapy, with their success hinging on effective systems to boost anti‐tumor immunity. Biological membranes are not only a delivery vehicle but also source of antigens and adjuvants, garnering growing interest in vaccine research. This review starts an introduction the composition mechanisms cancer describes sources, advantages/disadvantages, engineering strategies, applications these membrane‐based platforms development. offers critical analysis discusses further direction platform view clinical translation immunotherapy.

Language: Английский

Citations

0
Pharmaceutical Analysis of Protein–Peptide Coformulations and the Influence of Polysorbates DOI Creative Commons
Joseph Whiteley, Susanna Abrahmsén‐Alami,

Jonathan Booth

et al.

Molecular Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown

Published: April 30, 2025

Coformulation is an approach to formulating multiple biopharmaceutical therapeutics in a single formulation, promising the benefits of both therapies one dose. However, as molecular stability key consideration traditional formulations, coformulations will require extensive investigation. This study evaluated effects formulation stabilizers, specifically surfactants, at different grades, namely, regular grade (RG) Tween 20 and 80 Super-refined Polysorbate 80. Their were assessed through their interactions with human serum albumin (HSA) glucagon-like peptide-1 (GLP-1) receptor agonist (MEDI7219). Isothermal titration calorimetry (ITC) differential scanning (DSC) implemented determine strength binding thermal tertiary system. ITC confirmed that upon MEDI7219 into solution HSA RG, affinity peptide was reduced, resulting negatively cooperative binding. when titrated grades 80, increased positive DSC established similar extent polysorbates. Combining polysorbate did not further increase HSA; however, it reduce unfolding molecules absence heat. Overall, unique findings this have demonstrated order addition ternary coformulation affects final composition which important for pharmaceutical development.

Language: Английский

Citations

0
Comparative study of trastuzumab modification analysis using mono/multi-epitope affinity technology with LC-QTOF-MS DOI Creative Commons

Chengyi Zuo,

Jingwei Zhou,

Sumin Bian

et al.

Journal of Pharmaceutical Analysis, Journal Year: 2024, Volume and Issue: 14(11), P. 101015 - 101015

Published: June 5, 2024

Dynamic tracking analysis of monoclonal antibodies (mAbs) biotransformation

Language: Английский

Citations

3
Revolutionizing cancer treatment: The power of dendritic cell-based vaccines in immunotherapy DOI Open Access
Mohsen Sheykhhasan, Amirhossein Ahmadieh-Yazdi, Reza Heidari

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 184, P. 117858 - 117858

Published: Feb. 16, 2025

Language: Английский

Citations

0
Unveiling the immunological landscape: comprehensive characterization of neoantigen-reactive immune cells in neoantigen cancer vaccines DOI Creative Commons
Weijiang Liu, Hong Su, Peng Guo

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 18, 2025

Neoantigen-based cancer vaccine therapy represents a promising precision oncology strategy that targets unique tumor-specific mutations to elicit robust immune response. This therapeutic approach is designed harness the host’s response against neoantigens eliminate cells. The efficacy of neoantigen vaccines dependents on coordinated action diverse cells, including T lymphocytes, dendritic B natural killer and macrophages. Each cell type plays distinct crucial role in recognizing, targeting, destroying malignant Understanding mechanisms governing both individual collective dynamics for success. comprehensive review systematically explores neoantigen-specific their dynamic interactions, clinical application progress, aiming unveil potential value future development treatment.

Language: Английский

Citations

0
Regulation of cancer stem cells and immunotherapy of glioblastoma (Review) DOI Open Access
Aleksandra A. Kosianova, Oleg Pak, Igor Bryukhovetskiy

et al.

Biomedical Reports, Journal Year: 2023, Volume and Issue: 20(2)

Published: Dec. 19, 2023

Glioblastoma (GB) is one of the most adverse diagnoses in oncology. Complex current treatment results a median survival 15 months. Resistance to associated with presence cancer stem cells (CSCs). The present review aimed analyze mechanisms CSC plasticity, showing particular role β‑catenin regulating vital functions CSCs, and describe molecular Wnt‑independent increase levels, which influenced by local microenvironment CSCs. also analyzed reasons for low effectiveness using medication regulation proposed development immunotherapy scenarios tumor cell vaccines, containing heterogenous able producing multidirectional antineoplastic immune response. Additionally, possibility managing lymphopenia transplanting hematopoietic from healthy sibling clofazimine or other repurposed drugs that reduce concentration CSCs was discussed study.

Language: Английский

Citations

9